WHWK · Whitehawk Therapeutics, Inc. · Webcasts, Transcripts & Audio
$3.41
-0.20 (-5.54%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$194.40M
Shares
57.01M
Volume · Oct 7
435.72K
Avg daily vol (3M)
380.09K
Whitehawk Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Whitehawk Therapeutics, Inc. (WHWK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$15.00M
−$5.28M
'20 Q2
20-08-12
·
$231,000
−$2.89M
'20 Q3
20-11-10
·
$3.44M
−$18.27M
'22 Q2
22-08-10
·
$4.25M
−$14.47M
'22 Q3
22-11-09
▼62.3%
$5.23M
−$13.91M
'22 Q4
23-03-28
▲154.3%
$5.87M
−$15.22M
'23 Q1
23-05-10
▲80.4%
$6.20M
−$17.97M
'23 Q2
23-08-09
▲21%
$6.33M
−$16.27M
'23 Q4
24-03-13
▼8.8%
$5.35M
−$18.29M
'24 Q1
24-05-08
▼0.4%
$6.18M
−$14.58M
'24 Q2
24-08-07
LATEST
▲14.4%
$7.24M
−$18.27M
'24 Q4
25-03-18
Conference
Investor event
2026-09-15
Whitehawk Therapeutics, Inc. (WHWK) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
Whitehawk Therapeutics, Inc. (WHWK) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY24 · Q4
2025-03-18
Whitehawk Therapeutics, Inc. (WHWK) Q4 2024 Earnings Call Transcript
Confident tone
Tumor target validation
Platform technology differentiation
ADC pipeline and portfolio
Revenue
$7.24M*
▲ 14.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-07
Whitehawk Therapeutics, Inc. (WHWK) Q2 2024 Earnings Call Transcript
Positive tone
PRECISION1 trial and TSC1/TSC2 interim data
FYARRO commercial performance in PEComa
Pipeline expansion: EEC and NET trials
Revenue
$6.18M
▼ 0.4% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Whitehawk Therapeutics, Inc. (WHWK) Q1 2024 Earnings Call Transcript
Positive tone
PRECISION1 trial enrollment and interim data
Endometrial (EEC) Phase II program
FYARRO commercial performance
Revenue
$5.35M
▼ 8.8% YoY Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Whitehawk Therapeutics, Inc. (WHWK) Q4 2023 Earnings Call
Revenue
$6.33M*
▲ 21% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q2
2023-08-09
Whitehawk Therapeutics, Inc. (WHWK) Q2 2023 Earnings Call
Revenue
$6.20M
▲ 80.4% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Whitehawk Therapeutics, Inc. (WHWK) Q1 2023 Earnings Call
Revenue
$5.87M
▲ 154.3% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Whitehawk Therapeutics, Inc. (WHWK) Q4 2022 Earnings Call
Revenue
$5.23M*
▼ 62.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Whitehawk Therapeutics, Inc. (WHWK) Q3 2022 Earnings Call
Revenue
$4.25M
Diluted EPS
$-0.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Whitehawk Therapeutics, Inc. (WHWK) Q2 2022 Earnings Call
Revenue
$3.44M
Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-11-10
Whitehawk Therapeutics, Inc. (WHWK) Q3 2020 Earnings Call
Revenue
$231,000
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Whitehawk Therapeutics, Inc. (WHWK) Q2 2020 Earnings Call
Revenue
$15.00M
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-16
Whitehawk Therapeutics, Inc. (WHWK) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–14 of 14 webcasts